Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis.

Butelman ER, Maremmani AGI, Bacciardi S, Chen CY, Correa da Rosa J, Kreek MJ.

Front Psychiatry. 2018 Jun 27;9:283. doi: 10.3389/fpsyt.2018.00283. eCollection 2018.

2.

Gender-specific association of functional prodynorphin 68 bp repeats with cannabis exposure in an African American cohort.

Yuferov V, Butelman ER, Kreek MJ.

Neuropsychiatr Dis Treat. 2018 Apr 16;14:1025-1034. doi: 10.2147/NDT.S159954. eCollection 2018.

3.

Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.

Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ.

Neuropsychopharmacology. 2018 Mar;43(4):928. doi: 10.1038/npp.2017.245.

4.

Medications for substance use disorders (SUD): emerging approaches.

Butelman ER, Kreek MJ.

Expert Opin Emerg Drugs. 2017 Dec;22(4):301-315. doi: 10.1080/14728214.2017.1395855. Epub 2017 Oct 30.

PMID:
29057665
5.

Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.

Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ.

Neuropsychopharmacology. 2018 Mar;43(4):739-750. doi: 10.1038/npp.2017.205. Epub 2017 Aug 31. Erratum in: Neuropsychopharmacology. 2018 Mar;43(4):928.

6.

Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?

Butelman ER, Bacciardi S, Maremmani AGI, Darst-Campbell M, Correa da Rosa J, Kreek MJ.

Am J Addict. 2017 Sep;26(6):632-639. doi: 10.1111/ajad.12578. Epub 2017 Jun 27.

PMID:
28654734
7.

"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".

Valenza M, Butelman ER, Kreek MJ.

Psychopharmacology (Berl). 2017 Aug;234(15):2219-2231. doi: 10.1007/s00213-017-4647-0. Epub 2017 May 27.

PMID:
28550455
8.

Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.

Randesi M, van den Brink W, Levran O, Blanken P, Butelman ER, Yuferov V, da Rosa JC, Ott J, van Ree JM, Kreek MJ.

Drug Alcohol Depend. 2016 Nov 1;168:164-169. doi: 10.1016/j.drugalcdep.2016.08.634. Epub 2016 Sep 5.

PMID:
27664554
9.

Adolescent oxycodone self administration alters subsequent oxycodone-induced conditioned place preference and anti-nociceptive effect in C57BL/6J mice in adulthood.

Zhang Y, Windisch K, Altschuler J, Rahm S, Butelman ER, Kreek MJ.

Neuropharmacology. 2016 Dec;111:314-322. doi: 10.1016/j.neuropharm.2016.09.005. Epub 2016 Sep 7.

10.

Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.

Butelman ER, Kreek MJ.

Curr Top Behav Neurosci. 2016 May 26. [Epub ahead of print]

PMID:
27225498
11.

Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration.

Valenza M, Picetti R, Yuferov V, Butelman ER, Kreek MJ.

Neuropharmacology. 2016 Jun;105:639-650. doi: 10.1016/j.neuropharm.2016.01.004. Epub 2016 Jan 9.

12.
13.
14.

Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type mice.

Zhang Y, Picetti R, Butelman ER, Ho A, Blendy JA, Kreek MJ.

Neuropsychopharmacology. 2015 Mar 13;40(5):1091-100. doi: 10.1038/npp.2014.286.

15.

Genetics of opiate addiction.

Reed B, Butelman ER, Yuferov V, Randesi M, Kreek MJ.

Curr Psychiatry Rep. 2014 Nov;16(11):504. doi: 10.1007/s11920-014-0504-6. Review.

PMID:
25209027
16.

LC-MS/MS quantification of salvinorin A from biological fluids.

Caspers MJ, Williams TD, Lovell KM, Lozama A, Butelman ER, Kreek MJ, Johnson M, Griffiths R, Maclean K, Prisinzano TE.

Anal Methods. 2013 Dec 21;5(24). doi: 10.1039/C3AY40810H.

17.

Neurocognitive and neuroinflammatory correlates of PDYN and OPRK1 mRNA expression in the anterior cingulate in postmortem brain of HIV-infected subjects.

Yuferov V, Butelman ER, Ho A, Morgello S, Kreek MJ.

J Neuroinflammation. 2014 Jan 9;11:5. doi: 10.1186/1742-2094-11-5.

18.

Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL/6 J mice.

Zhang Y, Mayer-Blackwell B, Schlussman SD, Randesi M, Butelman ER, Ho A, Ott J, Kreek MJ.

Psychopharmacology (Berl). 2014 Apr;231(7):1277-87. doi: 10.1007/s00213-013-3306-3. Epub 2013 Nov 13.

19.

Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression.

Mayer-Blackwell B, Schlussman SD, Butelman ER, Ho A, Ott J, Kreek MJ, Zhang Y.

Neuroscience. 2014 Jan 31;258:280-91. doi: 10.1016/j.neuroscience.2013.10.062. Epub 2013 Nov 9.

20.

Chronic escalating cocaine exposure, abstinence/withdrawal, and chronic re-exposure: effects on striatal dopamine and opioid systems in C57BL/6J mice.

Zhang Y, Schlussman SD, Rabkin J, Butelman ER, Ho A, Kreek MJ.

Neuropharmacology. 2013 Apr;67:259-66. doi: 10.1016/j.neuropharm.2012.10.015. Epub 2012 Nov 16.

21.

Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER.

J Clin Invest. 2012 Oct;122(10):3387-93. doi: 10.1172/JCI60390. Epub 2012 Oct 1. Review.

22.

κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Butelman ER, Yuferov V, Kreek MJ.

Trends Neurosci. 2012 Oct;35(10):587-96. doi: 10.1016/j.tins.2012.05.005. Epub 2012 Jun 16. Review.

23.

Effects of withdrawal from chronic escalating-dose binge cocaine on conditioned place preference to cocaine and striatal preproenkephalin mRNA in C57BL/6J mice.

Zhang Y, Schlussman SD, Butelman ER, Ho A, Kreek MJ.

Neuropharmacology. 2012 Aug;63(2):322-9. doi: 10.1016/j.neuropharm.2012.03.021. Epub 2012 Apr 4.

24.

Semisynthetic neoclerodanes as kappa opioid receptor probes.

Lovell KM, Vasiljevik T, Araya JJ, Lozama A, Prevatt-Smith KM, Day VW, Dersch CM, Rothman RB, Butelman ER, Kreek MJ, Prisinzano TE.

Bioorg Med Chem. 2012 May 1;20(9):3100-10. doi: 10.1016/j.bmc.2012.02.040. Epub 2012 Mar 1.

25.

Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Butelman ER, Caspers M, Lovell KM, Kreek MJ, Prisinzano TE.

J Pharmacol Exp Ther. 2012 Jun;341(3):802-8. doi: 10.1124/jpet.112.193227. Epub 2012 Mar 20.

26.

Dose preference and dose escalation in extended-access cocaine self-administration in Fischer and Lewis rats.

Picetti R, Ho A, Butelman ER, Kreek MJ.

Psychopharmacology (Berl). 2010 Aug;211(3):313-23. doi: 10.1007/s00213-010-1899-3. Epub 2010 Jun 19.

27.

Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission.

Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T.

Trends Pharmacol Sci. 2010 Jul;31(7):299-305. doi: 10.1016/j.tips.2010.04.003. Epub 2010 May 12.

PMID:
20471111
28.

The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Butelman ER, Rus S, Prisinzano TE, Kreek MJ.

Psychopharmacology (Berl). 2010 Jun;210(2):253-62. doi: 10.1007/s00213-009-1771-5. Epub 2010 Jan 19.

29.

PET imaging of leptin biodistribution and metabolism in rodents and primates.

Ceccarini G, Flavell RR, Butelman ER, Synan M, Willnow TE, Bar-Dagan M, Goldsmith SJ, Kreek MJ, Kothari P, Vallabhajosula S, Muir TW, Friedman JM.

Cell Metab. 2009 Aug;10(2):148-59. doi: 10.1016/j.cmet.2009.07.001.

30.

Opiate and cocaine addiction: from bench to clinic and back to the bench.

Kreek MJ, Zhou Y, Butelman ER, Levran O.

Curr Opin Pharmacol. 2009 Feb;9(1):74-80. doi: 10.1016/j.coph.2008.12.016. Epub 2009 Jan 18. Review.

31.

Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid.

Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ.

J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. doi: 10.1124/jpet.108.145342. Epub 2008 Nov 10.

32.

Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice.

Zhang Y, Picetti R, Butelman ER, Schlussman SD, Ho A, Kreek MJ.

Neuropsychopharmacology. 2009 Mar;34(4):912-22. doi: 10.1038/npp.2008.134. Epub 2008 Sep 10.

33.

Bidirectional translational research: Progress in understanding addictive diseases.

Kreek MJ, Schlussman SD, Reed B, Zhang Y, Nielsen DA, Levran O, Zhou Y, Butelman ER.

Neuropharmacology. 2009;56 Suppl 1:32-43. doi: 10.1016/j.neuropharm.2008.07.042. Epub 2008 Aug 7. Review.

34.

The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.

Butelman ER, Rus S, Simpson DS, Wolf A, Prisinzano TE, Kreek MJ.

J Pharmacol Exp Ther. 2008 Oct;327(1):154-60. doi: 10.1124/jpet.108.140079. Epub 2008 Jul 1.

35.

Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates.

Butelman ER, Reed B, Chait BT, Mandau M, Yuferov V, Kreek MJ.

Psychoneuroendocrinology. 2008 Apr;33(3):292-304. doi: 10.1016/j.psyneuen.2007.11.011. Epub 2008 Jan 2.

36.

Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.

Hawkinson JE, Szoke BG, Garofalo AW, Hom DS, Zhang H, Dreyer M, Fukuda JY, Chen L, Samant B, Simmonds S, Zeitz KP, Wadsworth A, Liao A, Chavez RA, Zmolek W, Ruslim L, Bova MP, Holcomb R, Butelman ER, Ko MC, Malmberg AB.

J Pharmacol Exp Ther. 2007 Aug;322(2):619-30. Epub 2007 Apr 30.

37.

Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ.

J Pharmacol Exp Ther. 2007 Jan;320(1):300-6. Epub 2006 Oct 23.

38.

Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction.

Kreek MJ, Nielsen DA, Butelman ER, LaForge KS.

Nat Neurosci. 2005 Nov;8(11):1450-7. Review.

PMID:
16251987
39.

Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, Prisinzano TE.

Synapse. 2005 Dec 1;58(3):208-10.

PMID:
16138318
40.

Biological clock: biological clocks may modulate drug addiction.

Yuferov V, Butelman ER, Kreek MJ.

Eur J Hum Genet. 2005 Oct;13(10):1101-3. No abstract available.

41.

Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.

Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE.

J Med Chem. 2005 Jul 28;48(15):4765-71.

PMID:
16033256
42.

11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons.

Talbot PS, Narendran R, Butelman ER, Huang Y, Ngo K, Slifstein M, Martinez D, Laruelle M, Hwang DR.

J Nucl Med. 2005 Mar;46(3):484-94.

43.

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization.

Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ, Murry DJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Apr 25;818(2):221-5.

PMID:
15734162
44.
45.

Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA.

Kreek MJ, Schlussman SD, Bart G, Laforge KS, Butelman ER.

Neuropharmacology. 2004;47 Suppl 1:324-44. Review.

PMID:
15464148
46.

Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates.

Butelman ER, Harris TJ, Kreek MJ.

J Pharmacol Exp Ther. 2004 Oct;311(1):155-63. Epub 2004 May 19.

47.

Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ.

Psychopharmacology (Berl). 2004 Apr;173(1-2):146-52. Epub 2004 Jan 8.

PMID:
14712342
48.

Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ.

Psychopharmacology (Berl). 2004 Apr;172(4):422-9. Epub 2004 Jan 8.

PMID:
14712335
49.
50.

The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Butelman ER, Harris TJ, Kreek MJ.

Psychopharmacology (Berl). 2004 Mar;172(2):220-4. Epub 2003 Oct 30.

PMID:
14586540

Supplemental Content

Loading ...
Support Center